Previous 10 | Next 10 |
Danaher Corporation (DHR) is expected to report $1.83 for Q3 2023
2023-10-23 11:38:00 ET More on Danaher Danaher: Short-Term Headwinds, But Long-Term Tailwinds Veralto: Thoughts On The Danaher Spinoff Should Danaher Investors Sell New Veralto Shares? Abcam holders should vote for sale to Danaher, proxy adviser ISS says (upd...
2023-10-23 07:00:00 ET Summary Investing is a learning process that requires time and a willingness to learn from mistakes and successes. Starting with a 1% portfolio weighting and not rebalancing allows winners to compound while limiting losses. Having a meaningful sample siz...
2023-10-22 07:42:01 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The D...
2023-10-19 11:30:00 ET Summary The Akre Focus Fund invests in a small number of what we believe to be extraordinary businesses that are run by talented and honest managers who wisely reinvest free cash flow. The Fund's performance for Q3 2023 was -4.10%, compared to the S&P 50...
2023-10-19 01:20:00 ET Summary Baron Health Care Fund invests in companies engaged in the research, development, production, sale, delivery, or distribution of products and services related to the health care industry. The Fund trailed the Benchmark by 217 basis points this quarte...
2023-10-17 11:05:44 ET Summary Danaher is currently rated as a hold as the stock price has not reached attractive levels yet. The demand for Danaher's products in the biopharma industry has declined due to destocking and reduced investment in the sector. Danaher's solid positi...
2023-10-16 14:56:57 ET Summary The Health Care Select Sector SPDR Fund is an ETF that tracks the performance of the U.S. health care sector. XLV has a diverse portfolio of holdings, including well-known companies like Eli Lilly, UnitedHealth Group, and Johnson & Johnson. T...
2023-10-16 12:27:11 ET Summary Sartorius is facing challenging business conditions due to destocking and delayed customer investment. The company's ability to maintain high levels of sustained growth is a concern due to increasing competition and financing costs. We downgrade ...
2023-10-16 11:00:12 ET More on Abcam ADS Abcam: Further Upside Limited With Potential Acquisition In The Making, Reiterate Hold Abcam received multiple bids in sales process, contacted over 30 parties Abcam founder looking at various options amid Danaher takeover - r...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...
Beckman Coulter's DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.'s Annual Supplier Innovation Celebration PR Newswire BREA, Calif. , July 25, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the Dx...
2024-07-23 20:30:03 ET Goldman Sachs analyst issues NEUTRAL recommendation for DHR on July 23, 2024 06:19PM ET. The previous analyst recommendation was Neutral. DHR was trading at $264.18 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cu...